Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma

Glioblastoma Multiforme Clinical Trial

Official title:

A Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MRI Imaging Criteria in Patients With Progressive and/or Recurrent Malignant Glioma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00591058
• Other study ID #: TM601-007
• Status: Active, not recruiting
• Phase: Phase 1
• First received: December 27, 2007
• Last updated: July 16, 2009
• Start date: February 2008
• Est. completion date: February 2010

Study information

• Verified date: July 2009
• Source: TransMolecular
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and biologically active dose of TM-601 in adult patients with recurrent malignant glioma.

Description:

This Phase I study will evaluate the safety of TM-601 in patients with recurrent malignant glioma who have failed first-line, standard therapy.

Study patients will be assigned to receive treatment in 1 of 6 treatment cohorts. Patients will be assigned to each dose level in groups of 3-6 (depending upon treatment response seen within each cohort), with escalation to the next highest dose dependent upon demonstrated tolerance in the previous dosing group.

Patients will be administered an imaging dose of 131I-TM-601, intravenously, to demonstrate tumor-specific localization prior to study treatment with non-labeled TM-601. Eligible patients demonstrating tumor-specific imaging will be assigned to a treatment cohort and will received non-labeled TM-601 once a week for 3 weeks, followed by clinical follow-up visits and MR imaging.

Data from this study will help determine the IV dose of TM-601 required to produce MR perfusion changes (as well as other biomarker changes) in patients with recurrent malignant glioma. It is not known whether participation in this trial will provide patients with benefit in terms of improved tumor control, although pre-clinical evidence and evidence from other clinical trials with 131I TM-601 suggest that TM-601 is an active agent in malignant glioma.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 36
• Est. completion date: February 2010
• Est. primary completion date: February 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients Must:

1. Have histologically proven malignant glioma (anaplastic astrocytoma, anaplastic oligodendroglioma or glioblastoma multiforme) which is progressive or recurrent after external beam radiation therapy (to at least 50 Gy) ± chemotherapy. Patients with previous low grade glioma who progressed after radiotherapy ± chemotherapy and are biopsied and found to have a high grade glioma are eligible.

2. Be =18 years of age.

3. Have a baseline Karnofsky Performance status of =60%

4. Have a Mini Mental State Exam score = 19.

5. Have a life expectancy, based on the Investigator's judgment, of >3 months.

6. On screening ECG, have a QTc interval of <450 ms.

7. If taking steroids, be on a dose that is stable for at least 5 days prior to the imaging dose.

8. Have recovered from the toxicity of all previous therapy prior to enrollment. If the patient has undergone recent major surgery, an interval of at least 3 weeks must have elapsed between the surgery and the date of the imaging dose.

9. Have adequate organ and marrow function as defined below:

hemoglobin >9.0g/dL absolute neutrophil count >1,500 mm3 platelet count >100,000 mm3 prothrombin time <1.5 ULN partial thromboplastin time (PTT) <1.5 ULN total bilirubin < 2.0 mg/dL AST(SGOT)/ALT(SGPT) <5 x institutional ULN creatinine (serum) =2.0 mg/dL*

*If serum creatinine is >2.0 then creatinine clearance must be =60 ml/min

10. Have a negative serum and urine pregnancy test within 14 days of study drug administration, if female and of child bearing potential.

11. Agree to use an effective form of contraception to avoid pregnancy, if fertile (applicable to both male and female patients).

12. Agree to refrain from nursing, if female.

13. Have signed and dated written informed consent.

14. Be able to comply with treatment plan, study procedures and follow-up examinations.

Exclusion Criteria:

Patients may NOT:

1. Have a serious concurrent infection or medical illness which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety. (Examples of medical illnesses are [but not limited to] the following: uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.)

2. Have a prior malignancy with less than 5-year disease free interval, except for adequately treated basal cell or squamous cell carcinoma of the skin, or in situ cancer of the cervix.

3. Be pregnant or breast-feeding.

4. Have received radiation treatments = 3 months from time of first study drug administration.

5. Have received any cytotoxic chemotherapy, whether conventional or investigational, = 4 weeks prior to enrollment in this study (6 weeks for mitomycin-C or nitrosoureas).

6. Have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to 131I-TM-601 e.g. iodine or iodine-containing drugs.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Astrocytoma
• GBM
• Glioblastoma
• Glioblastoma Multiforme
• Glioma
• Malignant Glioma
• Oligodendroglioma

Intervention

Drug:
• TM-601
TM-601, administered intravenously (IV), once/week for 3 weeks

Locations

Country	Name	City	State
United States	University of Alabama	Birmingham	Alabama
United States	Northwestern University	Chicago	Illinois
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Columbia University	New York	New York
United States	University of Washington	Seattle	Washington
United States	Washington University	St. Louis	Missouri
United States	Wake Forest University	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
TransMolecular

Country where clinical trial is conducted

United States, 

References & Publications (4)

Hockaday DC, Shen S, Fiveash J, Raubitschek A, Colcher D, Liu A, Alvarez V, Mamelak AN. Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6. — View Citation

Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 2002 Aug;39(2):162-73. — View Citation

Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007 Mar;4(2):175-86. Review. — View Citation

Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. 2006 Aug 1;24(22):3644-50. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the safety profile/tolerability of TM-601 in this patient population, based on adverse event incidence, severity, duration, causality, seriousness and type as well as by physical examination, vital signs and clinical laboratory assessments.		Throughout the treatment phase of the study for each study patient, and for 28 days following the final study dose.	Yes
Secondary	A primary objective of this study is to evaluate the biologically active dose of TM-601 in this population of patients based on changes in perfusion MRI parameters.		At the completion of the dosing cycle for each patient, and at 28 days following the patient's final study treatment.	No